Jitka Smetanova, Zuzana Strizova, Anna Sediva, Tomas Milota, Rudolf Horvath. The Lancet Rheumatology. 2021 December 21. doi: 10.1016/S2665-9913(21)00393-3. IF: 35, 48
Mgr. Jitka Smetanová, Ústav imunologie 2. lékařské fakulty a FN Motol
"Biologic disease-modifying anti-rheumatic drugs (DMARDs) represent a potent treatment option for patients with immune-mediated inflammatory diseases. Yet, infections make up the largest proportion of serious adverse events associated with biological DMARD therapy. Throughout the COVID-19 pandemic, patients receiving immunosuppressive treatment were shown to be at higher risk of severe disease outcomes.Vaccination could prevent these outcomes, but the efficacy of COVID-19 vaccines in these patients is incompletely understood. Although studies investigating the effect of biological DMARDs on the development of immune responses to COVID-19 vaccines are slowly accumulating, most of our current knowledge relies on studies evaluating the serological responses to COVID-19 vaccines. However, the serological response to COVID-19 vaccines is highly variable between individuals, in terms of both antibody titres and kinetics.There is also no cutoff value of antibody titres that clearly reflects protection from SARS-CoV-2 infection." Continue reading on The Lancet Rheumatology, December 21, 2021.
